Orthopaedic Journal of Sports Medicine · Oct 16, 2026

Dual Versus Single Incretin Receptor Agonism and Outcomes After Arthroscopic Rotator Cuff Repair: Comparing Tirzepatide Versus Semaglutide

By Thota PK, Pandya S, Kelly AM et al.

BACKGROUND: Single incretin receptor agonists, such as semaglutide, are associated with improved postoperative outcomes after arthroscopic rotator cuff repair (ARCR) in diabetic patients. Dual incretin receptor agonism may differ from single glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonism in its effects on postoperative recovery, but comparative outcomes after ARCR have not been investigated. PURPOSE: To compare outcomes after ARCR between patients on preoperative dual incretin receptor agonism (tirzepatide) versus single incretin receptor agonism (semaglutide) and evaluate the effects of these incretin therapies versus no exposure. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: Using the TriNetX Database, patients aged between 40 and 80 years who underwent primary ARCR were stratified by preoperative exposure to tirzepatide or semaglutide within 12 months of surgery. Two 1-to-1 propensity-matched analyses were performed. Match 1 compared tirzepatide versus semaglutide, and Match 2 compared patients on either drug to controls on neither medication. Matching variables included various demographic and comorbidity characteristics. The primary outcome was subsequent rotator cuff repair (RCR) coding, defined as a repeat Current Procedural Terminology 29827 after the index procedure. Secondary outcomes included complete tear recurrence, opioid utilization, and physical therapy utilization. Outcomes were assessed at 90 days, 1 year, and 2 years. Relative risks (RR) with 95% CIs were calculated. RESULTS: In Match 1, tirzepatide was associated with a significantly lower 2-year rate of subsequent RCR compared with semaglutide (2.83% vs 5.67%; RR, 0.500; P = .008). Opioid use (48.2% vs 55.7%; RR, 0.865; P = .005) and physical therapy utilization (36.5% vs 42.5%; RR, 0.860; P = .022) were also significantly lower in the tirzepatide cohort at 2 years. In Match 2, use of either drug was associated with significantly lower complete tear recurrence at 90 days (RR, 0.828; P = .0006), 1 year (RR, 0.849; P = .0006), and 2 years (RR, 0.841; P = .0002), as well as reduced opioid use at 1 year (RR, 0.937; P = .013) and 2 years (RR, 0.905; P < .0001) compared to controls. CONCLUSION: After ARCR, dual incretin receptor agonism with tirzepatide was associated with lower 2-year rates of subsequent RCR coding, opioid utilization, and physical therapy utilization compared with exclusive GLP-1 receptor agonism with semaglutide. These findings describe differences in subsequent procedure coding and health care utilization rather than confirmed structural healing.

doi.org/10.1177/23259671261490664Open accessPubMed 43047762Populations

AgingResearch.News